Dimerix has announced a new patent family application to protect the results from its mouse study of DMX-700 in COPD.

Aussie clinical stage biotech Dimerix (ASX:DXB) has just announced a new patent family application to protect the surprising outcomes observed in the recent DMX-700 animal study in Chronic Obstructive Pulmonary Disease (COPD).

In that study, the activity of DMX-700 was tested in mice using an oral dose delivery in the porcine pancreatic elastase (PPE) model of COPD.

PPE is the most common model as it mimics the inflammatory response that leads to the breakdown of lung tissue and emphysema (or shortness of breath).

The results showed that DMX-700 demonstrated statistically significant 80% reduction versus control in induced lung injury in mice (p<0.01, n=6).


Surprising results

COPD is a progressive and life-threatening lung disease, and is the third leading cause of death worldwide, causing 3.23 million deaths in 2019.

The global COPD treatment market was valued at almost US$18 billion in 2021, and is projected to  grow at a CAGR of 7.28% to reach US$27 billion by 2027.

DMX-700 treats COPD by simultaneously blocking Interleukin 8 receptor beta (IL-8Rβ), and an angiotensin II type 1 (AT1R).

It’s already been demonstrated that inhibiting only AT1R or IL-8Rβ individually had no statistically significant effect on lung injury induced by PPE.

What was surprising about the latest result was that the use of an IL-8Rβ inhibitor along with certain doses of an angiotensin type 1 receptor blocker (ARB) were more effective in the treatment of COPD-related lung injury.

Specifically, it was shown that certain doses of ARBs are more effective together with IL-8Rβ inhibitors.

Dimerix says the details of the dosing used will be published in due course in order to protect the confidential status of discovery.


Global patent

This new patent application is a key step for Dimerix to launch itself in the potentially huge COPD treatment market.

It will also secure ownership over what Dimerix believes is an important new drug discovery.

The new provisional patent application is titled “Dosage regimen for the treatment of COPD”.

If granted, it would give Dimerix IP protection up to 2043.

The new patent application also bolsters the existing DMX-700 global patent application filed in September 2020.

It is anticipated that, DMX-700 will be protected by Composition of Matter patents, Formulation patents and Method of Use patents – providing the company with a strong competitive position.


Clinical trial planned

The DMX-700 compounds individually have a known safety profile in human studies, meaning DMX-700 may potentially move directly into clinical studies.

The clinical trial will now be designed, along with any further required nonclinical safety studies, and is expected to commence in the first half of 2023.

In addition, Dimerix continues to drive its flagship program, the Phase 3 ACTION3 pivotal study of DMX-200 in FSGS (Focal segmental glomerulosclerosis) –  a rare disease that affects filters in the kidney.

“This is clearly a very exciting and busy time for Dimerix at the moment with multiple activities that could each add significant value to the company”, says Dr Nina Webster, CEO of Dimerix.

“Our flagship Phase 3 program in FSGS is progressing well.

“And now our second pipeline candidate, DMX-700, has demonstrated some very encouraging pre-clinical data.

“The DMX-700 study identified some very surprising outcomes, which we believe further strengthens our IP position moving forward,” she added.


This article was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.